Acrivon Therapeutics, Inc. 8-K

What Happened
Acrivon Therapeutics, Inc. (ACRV) filed an 8-K on February 27, 2026 under Item 7.01 (Regulation FD Disclosure) to report a live webcast of a company‑sponsored key opinion leader (KOL) panel held during the European Society of Gynecological Oncology (ESGO) Congress in Copenhagen. The panel discussed interim clinical data from Acrivon’s ACR‑368 Phase 2b registrational‑intent trial, future plans, and KOL perspectives on ACR‑368’s potential to address unmet needs in endometrial cancer—particularly the serous sub‑type. Speakers participated both on‑site and virtually. The presentation slides were filed as Exhibit 99.1 and are incorporated by reference.

Key Details

• Event date: February 27, 2026 (webcast during ESGO Congress in Copenhagen).
• Program: KOL panel covering interim ACR‑368 Phase 2b registrational‑intent clinical data and future plans.
• Focus: Potential for ACR‑368 in endometrial cancer, with emphasis on the serous sub‑type.
• Disclosure: Slides from the presentation attached as Exhibit 99.1 to the 8‑K.

Why It Matters
This filing is a Regulation FD disclosure—Acrivon publicly shared clinical program updates and expert commentary rather than private communications—so all investors have access to the same information. For investors tracking ACR‑368, the webcast and slides provide additional detail on interim Phase 2b data, the company’s development plans, and independent KOL views, which could inform assessments of clinical progress and potential regulatory or commercial prospects. This 8‑K does not report financial results or changes in management; it documents public dissemination of trial-related information.